Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
Filed with ASX · · 5 pages · English
Story so far
Earlier from Imugene
- S&P DJI Announces December 2021 Quarterly Rebalance
- Clinical Trial Supply Agreement with Merck KGaA and Pfizer
- Investor Presentation Imugene Eureka Therapeutics
- First patient dosed in Phase I clinical trial of CHECKvacc
- Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
Later from Imugene
- FDA IND approval for the phase 2 clinical trial of HER-Vaxx
- Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
- South Korea HERVaxx Patent Grant
- Imugene Receives $6.54 million R&D Tax Incentive
- HER-Vaxx Immunotherapy Patent Granted in Europe
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene